Anticancer Fund
Acronym: ACF
General Information
Identification Code: 404359320127-95
Website: [object Object]
Entity Form: Foundation of Public Utility
Registration Category: Non-governmental organisations, platforms and networks and similar
Registration Date: 12/30/2015
Last Update: 3/13/2024
EP Accredited Number: 0
Mission & Interests
Goals: The Anticancer Fund is dedicated to expanding the range of treatment options available to patients, regardless of their commercial value.
The Anticancer Fund is a foundation of public utility with an international reach that focuses on the cure of cancer patients by:
- Supporting the development of promising cancer treatments that are currently neglected and bringing the most valuable treatments to the patient as quickly as possible.
- Providing free comprehensive, evidence-based information about cancer treatments.
Interests Represented: Does not represent commercial interests
Interests:
- Public health
- Research and innovation
Levels of Interest:
- global
Activities
Main EU Legislative Proposals: Europe’s Beating Cancer Plan
Horizon: EU4Health and Missions
New Pharmaceutical Strategy
MAC Group (Members of Parliament Against Cancer)
Cancer related policies
Research and clinical trials
Market authorisation for innovative medicines
Revision of the Pharmaceutical Legislation
Communication Activities: 1. Member of the Repurposing Observatory Group (RepOG)
2. Remedi4All was launched in September 2022: an ambitious EU-funded research initiative to drive forward the repurposing of medicines in Europe. The ACF is one of the consortium partners and has taken the lead in the organisation of the cancer path at the first international drug repurposing conference (#iDR24) that took place on 6 and 7 March 2024.
3. Targeted EU Contact Program on cancer related policy: Webinar to raise awareness among policymakers, researchers, physicians and patients of the potential of repurposed drugs in the treatment of cancer against the backdrop of the COVID-19 pandemic.
4. Stakeholder Contact Group EBCP
5. Since 2017, the ACF was invited for STAMP meetings on the topic of drug repurposing. The ACF actively contributed to drafting the framework proposal for drug repurposing.
6. BE Presidency invitation to joint meeting NCAPR/HTA-HAG/HMA related to Drug Repurposing Keynote Speach
7. Since 2019, the ACF has been providing feedback to the commission through surveys and public consultations on Europe’s beating cancer plan, the cancer mission, the pharmaceutical strategy, Revision of EU rules on medicines for children and rare diseases and on the revision of the pharmaceutical legislation.
On 21 may 2021, ACF was invited to participate in the Pharmaceutical Committee on the subject of: “Future proofing of the legislation and incentives for innovation that reaches the patient”.
8. The ACF formulates its recommendations to the Mission Board and has F-2-F meetings with different MEPs.
Inter-institutional or Unofficial Groupings: Cancer
Head Office
Address: Brusselsesteenweg 11
Post Code: 1860
City: Meise
Country: BELGIUM
Phone: [object Object]
EU Office
Address: Brusselsesteenweg 11
Post Code: 1860
City: Meise
Country: BELGIUM
Phone: [object Object]
Financial Data
New Organisation: false
Closed Year: [object Object]
Current Year: [object Object]
Complementary Information: The grant from EATRIS (REMEDI4ALL) for the amount of 91654 euro refers to the year 2024
Membership Information
Members10 Percent: 1
Members25 Percent: 1
Members50 Percent: 0
Members75 Percent: 0
Members: 3
Members F T E: 1.350000023841858
Structure
Structure Type: Structure
Is Member Of: https://www.anticancerfund.org/en/partners
Organisation Members: https://www.icrpartnership.org/
https://www.europeancancer.org/
https://bigagainstbreastcancer.org/collaborations/patient-advocates/ (BIG: Patient Partnership Initiative)
https://www.ovacure.org/en/ (Scientific Board)
https://c-path.org/programs/cdrc/ (Cure Drug Repurposing Collaboratory)
https://consilium-scientific.org/ (Advisory Board)